NCT06302608Active, not recruitingPhase 1
Clinical Trial on the Safety and Effectiveness of Subretinal Injection of NGGT001 for Treating Crystalline Retinal Degeneration
Xiamen Ophthalmology Center Affiliated to Xiamen University1 site in 1 country11 target enrollmentStarted: February 8, 2023Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 11
- Locations
- 1
- Primary Endpoint
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Study Overview
Brief Summary
Evaluate the safety and tolerability of NGGT001 subretinal injection for the treatment of crystalline retinal degeneration (BCD)
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years old;
- •Gender unlimited.
- •Diagnosed as crystalline retinal degeneration (BCD).
- •Molecular diagnosis confirms CYP4V2 mutation.
- •The best corrected visual acuity is less than 20/
- •Agree to take contraceptive measures within 1 year from the start of the study until administration.
- •Voluntarily sign an informed consent form.
Exclusion Criteria
- •Insufficient number of photoreceptor cells in the retina, such as retinal thickness less than 100 μ m. Or no atrophy or pigmentation in the posterior pole area<3- Retinal disc.
- •The presence of choroidal neovascularization or other eye lesions caused by BCD, which researchers believe may affect surgical procedures or interfere with the interpretation of clinical endpoints.
- •The use of therapeutic drugs within the first 6 months of enrollment may affect experimental observation, such as Lucentis, Avastin, Conbercept, Triamcinolone acetonide, steroids, etc;
- •The treatment eye has undergone intraocular surgery, such as PDT, vitrectomy, periocular vascular bypass surgery, etc., or requires intraocular surgery during clinical research, such as cataract surgery, retinal laser therapy, etc;
- •Used or may use systemic medications that may cause eye damage, such as psoralen, tamoxifen, etc;
- •Highly sensitive or allergic to the ingredients in the experimental drug (with a history of allergies to two or more drugs or foods);
- •Abnormal and clinically significant physical examination, vital signs, laboratory tests (such as blood routine, urine routine, blood biochemistry, coagulation function, immunological tests, etc.), or abnormal indicators deemed clinically significant by researchers;
- •There are diseases or medical histories that may affect drug safety or internal processes, especially cardiovascular, liver, kidney, endocrine, digestive, lung, neurological, hematological, tumor, immune or metabolic disorders that researchers consider clinically significant.
- •Participated in clinical trials of other drugs or medical devices within 3 months prior to enrollment;
- •Female patients during pregnancy or lactation;
- •Other researchers believe that it is not suitable to participate in the study.
Arms & Interventions
Dose Level 4
Experimental
Dose level 4 will be administered
Intervention: NGGT001 (Genetic)
Dose Level 3
Experimental
Dose level 3 will be administered
Intervention: NGGT001 (Genetic)
Dose level 2
Experimental
Dose level 2 will be administered
Intervention: NGGT001 (Genetic)
Dose level 1
Experimental
Dose level 1 will be administered
Intervention: NGGT001 (Genetic)
Outcomes
Primary Outcomes
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: 1 year
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
BCVA
Time Frame: 1 year
ETDRS visual acuity
Secondary Outcomes
- Change from baseline in best-corrected visual acuity(Baseline and Months 1, 2, 3, 4, 5, 6, 9, and 12; the primary efficacy assessment is the change from baseline at Month 12.)
- Change from baseline in retinal sensitivity assessed by microperimetry(Baseline to Month 12)
- Change from baseline in contrast sensitivity(From baseline at Month 12)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy SubjectsBietti Crystalline Corneoretinal DystrophyNCT06706427NGGT (Suzhou) Biotechnology Co., Ltd.12
Completed
Phase 1
ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular DegenerationGeographic AtrophyNCT04744662ONL Therapeutics28
Completed
Phase 1
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)Macular EdemaRetinal Vein OcclusionNCT01027650Allergan121
Terminated
Phase 2
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)Macular Degeneration, Age-RelatedGeographic AtrophyNCT03972709Genentech, Inc.372
Recruiting
Phase 1
A Study of GenSci098 in Subjects With Active Thyroid Eye DiseaseSafetyTolerabilityGenSci098Thyroid Eye Disease (TED)NCT06569758Changchun GeneScience Pharmaceutical Co., Ltd.76